


In the Abstract

The invention relates to N-[(piperazinyl)hetaryl]arylsulfonamide compounds of the general formula I



in which

Q is a bivalent, 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents R^a which is/are selected, independently of each other, from halogen, CN, NO_2 , CO_2R^4 , COR^5 , $\text{C}_1\text{-C}_4\text{-alkyl}$ and $\text{C}_1\text{-C}_4\text{-haloalkyl}$;

Ar is phenyl or a 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents R^b , which is/are selected from halogen, NO_2 , CN, CO_2R^4 , COR^5 , $\text{C}_1\text{-C}_6\text{-alkyl}$, $\text{C}_2\text{-C}_6\text{-alkenyl}$, $\text{C}_2\text{-C}_6\text{-alkynyl}$, $\text{C}_3\text{-C}_6\text{-cycloalkyl}$, $\text{C}_3\text{-C}_6\text{-cycloalkyl-C}_1\text{-C}_4\text{-alkyl}$ and $\text{C}_1\text{-C}_4\text{-haloalkyl}$, with it also being possible for two radicals R^b which are bonded to adjacent C atoms of Ar to be together $\text{C}_3\text{-C}_4\text{-alkylene}$;

R^1 is hydrogen, $\text{C}_1\text{-C}_4\text{-alkyl}$, $\text{C}_1\text{-C}_4\text{-haloalkyl}$, $\text{C}_3\text{-C}_6\text{-cycloalkyl}$, $\text{C}_3\text{-C}_6\text{-cycloalkyl-C}_1\text{-C}_4\text{-alkyl}$, $\text{C}_1\text{-C}_4\text{-hydroxyalkyl}$, $\text{C}_1\text{-C}_4\text{-alkoxy-C}_1\text{-C}_4\text{-alkyl}$, $\text{C}_3\text{-C}_4\text{-alkenyl}$ or $\text{C}_3\text{-C}_4\text{-alkynyl}$;

with the radicals n, R^1 , R^2 , R^3 , R^4 and R^5 having the meanings given in the patent claims, to the N-oxides and to the physiologically tolerated acid addition salts of these compounds and to pharmaceutical compositions which comprise at least one N-[(piperazinyl)hetaryl]arylsulfonamide compound as claimed in one of claims 1 to 10 and/or at least one physiologically tolerated acid addition salt of I and/or an N-oxide of I, where appropriate together with physiologically acceptable carriers and/or auxiliary substances for treating diseases which respond to influencing by dopamine D_3 receptor antagonists or agonists, in particular for treating diseases of the central nervous system and disturbances of kidney function.